Trial Profile
A 24 Week Treatment, Multicenter, Randomized, Double Blinded, Double Dummy, Parallel-group, Clinical Trial Evaluating the Efficacy and Safety of Aclidinium Bromide 400 μg/Formoterol Fumarate 12 μg Fixed-dose Combination BID Compared With Each Monotherapy (Aclidinium Bromide 400 μg BID and Formoterol Fumarate 12 μg BID) and Tiotropium 18 μg QD When Administered to Patients With Stable Chronic Obstructive Pulmonary Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Oct 2019
Price :
$35
*
At a glance
- Drugs Aclidinium bromide/formoterol (Primary) ; Aclidinium bromide; Formoterol; Tiotropium bromide
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Acronyms AMPLIFY
- Sponsors AstraZeneca
- 22 Oct 2019 According to a Circassia media release, results have been presented at Respiratory Educational Reception at the American College of Chest Physicians CHEST Annual Meeting 2019.
- 17 Apr 2019 According to a Circassia media release, the product is approved worldwide, including in the European Union, under a number of brand names.
- 17 Apr 2019 According to a Circassia media release, findings from the study were published online March 22, 2019 in the International Journal of COPD originally published by Dove Medical Press Ltd International Journal of COPD.